Bevantolol - SOM Biotech

Drug Profile

Bevantolol - SOM Biotech

Alternative Names: SOM3355

Latest Information Update: 31 Oct 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Nippon Chemiphar
  • Developer SOM Biotech
  • Class Antihypertensives; Ischaemic heart disorder therapies; Small molecules
  • Mechanism of Action Vesicular monoamine transporter 2 inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No
  • Available For Licensing Yes

Highest Development Phases

  • Clinical Phase Unknown Huntington's disease

Most Recent Events

  • 30 Oct 2017 Chemical structure information added
  • 11 Oct 2017 Bevantolol licensed to SOM Biotech worldwide except Asia
  • 11 Oct 2017 SOM Biotech intends to initiate a phase IIa proof-of-concept trial for Huntington's disease in Europe, in December 2017
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top